ArticleFrontiers in oncology2025
Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although multiple guidelines for managing severe immune-mediated hepatotoxicity (IMH) induced by immune checkpoint inhibitors (ICIs) were recommended, real-world research data regarding its clinical progression, treatment modalities, and outcomes remain scarce. Methods: This study was a retrospective, single-center investigation conducted at the Fourth Hospital of Hebei Medical University. A total of 379 patients with complete clinical records were enrolled in the Department of Immunology and Rheumatology at the Fourth Hospital of Hebei Medical University from January 2021 to July 2024. Binary logistic regression analysis was employed to identify potential risk factors associated with the development of severe IMH or infection during treatment. Receiver operating characteristic (ROC) curve analysis was further applied to determine the optimal cutoff values for the identified risk factors. Results: A total of 32 severe IMH patients were analyzed for risk factor association; the Eastern Cooperative Oncology Group performance status (ECOG PS) (p = 0.001) and oral traditional Chinese medicine (TCM) (p < 0.001) were independently associated with the incidence of severe IMH. Based on our experience with these 32 patients, a road map was proposed for the management of severe IMH patients: conventional applications of daily methylprednisolone sodium succinate with dose adjustment for 11 days, a liver biopsy to exclude vanishing bile duct syndrome for steroid-resistant patients, and subsequent plasma exchange (PE). Furthermore, cumulative steroid use was identified as an independent risk factor for concurrent infection with a cutoff value of 1,656 mg (p = 0.024) in severe IMH patients. Conclusion: We investigated the risk factor of severe IMH and provided a feasible treatment roadmap for severe IMH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.